NCT06427226 2026-04-17
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Tanta University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT07310433 2025-12-30
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
Phase 2 Not yet recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT06888505 2025-09-18
DAPA-AIC
Hawler Medical University
Phase 2 Completed
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT06341842 2024-04-02
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Unknown
NCT05025735 2021-10-19
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Saint Luke's Health System
Phase 2 Unknown